FrancophonIA/ELRC3.0 huggingface dataset:
English: - In addition to routine pharmacovigilance activities, identified and potential risks highlighted for increased monitoring and follow-up should include heart failure, hepatic failure, interstitial lung disease, breast cancer, and reports concerning pregnancy in partners of patients taking bicalutamide.
Estonian: - Lisaks tavapärastele ravimiohutuse järelevalve alastele tegevustele tuleb tugevdada järelevalvet ja järelkontrolli muu hulgas järgmiste väljaselgitatud ja võimalike riskide suhtes: südamepuudulikkus, maksapuudulikkus, interstitsiaalne kopsuhaigus, rinnavähk ja bikalutamiidi kasutavate patsientide partnerite raseduse andmed.
English: Anti-androgens act against the effects of androgens (male sex hormones).
Estonian: Antiandrogeenid pärsivad androgeenide (meessuguhormoonide) toimeid.
English: A general trend with respect to quality of life in favour of bicalutamide 150 mg in comparison with castration was observed; the subgroups that provided these data showed significantly higher sexual appetence (p=0.029) and fitness (p=0.046).
Estonian: Täheldati üldist suundumust elukvaliteedi paranemise suunas bikalutamiid 150 mg kasuks võrreldes kastratsiooniga; alamgrupid, kust sellised andmed saadi, olid oluliselt kõrgema seksuaaltungiga (p=0,029) ja kehalise vormiga (p=0,046).
English: 3640 AE Mijdrecht The Netherlands
Estonian: Box 217 3640 AE Mijdrecht Madalmaad
English: Inhibition results in the regression of prostatic tumours.
Estonian: Inhibeerimine viib eesnäärmevähi regressioonini.
English: The United Kingdom
Estonian: Ühendkuningriik
English: TEVA Pharma B.V., Industrieweg 23, P.O.
Estonian: Industrieweg 23, P.O.
English: Therefore, clinicians may decide that the optimum medical strategy for a patient at low risk of disease progression, particularly in the adjuvant setting following radical prostatectomy, may be to defer hormonal therapy until signs that the disease is progressing.
Estonian: Seetõttu võivad arstid haiguse süvenemise madala ohuga patsientide korral, eriti adjuvantravis pärast radikaalset prostatektoomiat, pidada optimaalseks ravistrateegiaks hormoonravi alguse edasilükkamist kuni haiguse süvenemise nähtude ilmnemiseni.
English: The CHMP also concluded that a potential association between the use of bicalutamide 150 mg and heart failure could not be ruled out and therefore considered that the need to further study cardiovascular morbidity and mortality remains.
Estonian: Inimtervishoius kasutatavate ravimite komitee leidis ka, et bikalutamiidi 150 mg kasutamise ja südamepuudulikkuse vahelist võimalikku seost ei saa välistada ning et endiselt on vaja täiendavalt uurida südame- ja veresoonkonna haigustesse haigestumist ja neist haigustest põhjustatud suremust.
English: In these patients there was also a trend toward decreased survival compared with placebo patients (HR=1.16, 95% CI 0.99 to 1.37).
Estonian: Nendel patsientidel ilmnes ka kalduvus elulemuse langusele võrreldes platseeborühma patsientidega (riski suhe = 1,16; 95% CI 0,99 kuni 1,37).
English: Bicalutamide is a non-steroidal anti-androgen without any other endocrine activity.
Estonian: Bikalutamiid on mittesteroidne antiandrogeen, millel puudub muu endokriinne aktiivsus.
English: Bicaluplex 150 mg tablets are indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression (see section 5.1).
Estonian: Bicaluplex 150 mg tabletid on näidustatud kas üksi või radikaalse postatektoomia või kiiritusravi adjuvantravina patsientidel, kellel on lokaalne kaugelearenenud eesnäärmevähk ja kellel on kõrge risk haiguse progresseerumiseks (vt lõik 5.1).
English: Bicalutamide is a racemate, the (R)-enantiomer of which has most of the anti-androgen activity.
Estonian: Bikalutamiid on ratsemaat, mille antiandrogeenne aktiivsus tuleneb peamiselt (R)-enantiomeerist.
English: Combined analysis of 2 clinical studies comprising 805 patients with metastatic prostatic carcinoma, who had not been treated before with expected mortality 43%, showed that the treatment with bicalutamide 150 mg is less effective than castration as for the survival time (HR = 1.30 [confidence interval 1.04 - 1.65]).
Estonian: Kokku 805-l varem ravi mitte saanud metastaseerunud eesnäärmevähiga patsiendil läbiviidud 2 kliinilise uuringu kombineeritud analüüs näitas, et üldise 43%-lise eeldatava suremuse juures osutus elulemuse põhjal otsustades bikalutamiid vähem efektiivsemaks kui kastratsioon (riskisuhe =1,30 [usalduspiirid 1,04 kuni 1,65]).
English: acceptable for registration based on a positive benefit/risk ratio of bicalutamide 150mg containing products as recently assessed in the Casodex Article 31 Referral.
Estonian: registreerimist vastuvõetavaks, lähtudes bikalutamiidi 150 mg sisaldavate ravimite positiivsest kasulikkuse ja riski suhtest, mida hiljuti hinnati seoses ravimi Casodex kohta artikli 31 põhjal esitatud esildisega.
English: The effectiveness of bicalutamide 150 mg in the treatment of patients with locally advanced prostatic carcinoma without metastases, for whom primary treatment with hormones was indicated, was evaluated separately using the meta-analysis of two studies comprising 480 patients with prostatic carcinoma without metastases (M0) who had not been treated before.
Estonian: Bikalutamiid 150 mg efektiivsust lokaalse kaugelearenenud metastaseerumata eesnäärmevähiga patsientidel, kellele oli näidustatud esmane hormoonravi, hinnati eraldi, kasutades kahe uuringu, milles osales 480 eelnevalt ravi mitte saanud metastaseerumata eesnäärmevähiga patsienti (M0) metaanalüüsi.
English: Treatment discontinuation may result in antiandrogen withdrawal syndrome in some patients.
Estonian: Mõnedel patsientidel võib bikalutamiidravi lõpetamisel tekkida antiandrogeenne võõrutussündroom.
English: Bicalutamide 150 mg was studied as a treatment for patients with localized (T1-T2, N0 or NX, M0) or locally advanced (T3-T4, any N, M0; T1-T2, N+, M0) non-metastatic prostate cancer, in a combined analysis of 3 placebo-controlled double-blind studies in 8,113 patients, where the product was given as immediate hormone therapy or as adjuvant to radical prostatectomy or radiotherapy (primarily external beam radiation).
Estonian: Bikalutamiid 150 mg ravi analüüsiti kombineeritult piirdunud (T1-T2, N0 või NX, M0) või lokaalselt kaugelearenenud (T3-T4, kõik N, M0; T1-T2, N+, M0) metastaseerumata eesnäärmevähiga 8113 patsiendil läbiviidud 3 platseebo-kontrollitud, topeltpimeda uuringu tulemuste põhjal, kus bikalutamiidi kasutati ainsa hormoonravina või radikaalse prostatektoomia või kiiritusravi (eelkõige välise kiirega kiiritus) adjuvantravina.
English: No overall survival difference was seen at 7.4 years median follow-up with 22.9% mortality (HR = 0.99; 95% confidence interval 0.91 to 1.09).
Estonian: Üldises elulemuses ei täheldatud keskmiselt 7,4-aastase jälgimisperioodi jooksul erinevust, suremus 22,9% (riski suhe = 0,99; 95% usalduspiir 0,91 kuni 1,09).Vaatamata sellele ilmnesid uuringu alagruppide analüüsil mõningad suundumused.
English: Magyarország Rt Rákóczi út 70-72, Budapest, H-1074, Hungary
Estonian: TEVA Magyarország Rt Rákóczi út 70-72
English: The CHMP concluded that the benefit/risk balance of bicalutamide 150 mg containing medicinal products in the agreed restricted indication is favourable.
Estonian: Inimtervishoius kasutatavate ravimite komitee otsustas, et bikalutamiidi 150 mg sisaldavate ravimite kasulikkuse ja sellega seotud riski suhe on heakskiidetud piiratud näidustuse puhul soodne.
English: 0.81 (0.66 to 1.01)
Estonian: 0,81 (0,66 kuni 1,01)
English: 1.09 (0.85 to 1.39)
Estonian: 1,09 (0,85 kuni 1,39)
English: BicalutamidTeva 150 mg
Estonian: Bicalutamid-Teva 150 mg
English: Bicalutamide 150mg film-coated tablets (Ingers Industrial Solutions s.r.o.)
Estonian: Bicalutamide 150 mg õhukese polümeerikattega tabletid (Ingers Industrial Solutions s.r.o.)
English: 0.65 (0.44 to 0.95)
Estonian: 0,65 (0,44 kuni 0,95)
English: 0.60 (0.49 to 0.73)
Estonian: 0,60 (0,49 kuni 0,73)
English: 0.75 (0.61 to 0.91)
Estonian: 0,75 (0,61 kuni 0,91)
English: There was no significant difference in survival (HR=1.05 (CI=0.81-1.36), p=0.669) or in the interval until progression (HR=1.20 (CI 0.96-1.51), p=0.107) between the group treated with bicalutamide 150 mg and the group treated with castration.
Estonian: Puudus oluline erinevus 150 mg bikalutamiidiga ravitud ja kastratsiooni läbi teinud patsientide elulemuses (riski suhe = 1,05 (CI=0,81-1,36), p=0,669) või ajas progressioonini (riski suhe = 1,20 (CI 0,96 kuni 1,51), p=0,107).
English: Deaths (%) in placebo patients
Estonian: Surmad (%) platseebopatsientidel
English: OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF BICALUTAMIDE 150 mg CONTAINING MEDICINAL PRODUCTS
Estonian: BIKALUTAMIIDI 150 mg SISALDAVATE RAVIMITE TEADUSLIKU HINNANGU ÜLDKOKKUVÕTE
English: The scope of Bicaluplex Article 29 Referral concerns the benefit/risk ration of both indications: treatment of locally advanced prostatic cancer and monotherapy in early treatment or as adjunct to treatment with radiotherapy or radical prostatectomy in patients with prostate cancer.
Estonian: Artikli 29 kohane esildis ravimi Bicaluplex kohta käsitleb selle mõlema näidustusega - paikselt kaugelearenenud eesnäärmevähiga patsientide ravi ja monoteraapia ravi algul või kiiritusravi või radikaalse prostatektoomia lisaravi eesnäärmevähiga patsientidel - seotud kasulikkuse ja riski suhet.
English: Radiotherapy
Estonian: Kiiritusravi
English: The valid labelling text is the final version achieved during the Coordination group procedure.
Estonian: Koordineerimisrühma menetluse tulemusena saavutatud lõplik versioon on kehtiv märgistus.
English: 0.56 (0.40 to 0.78)
Estonian: 0,56 (0,40 kuni 0,78)
English: Bicalutamide is an oral-androgen used in the management of locally advanced prostate cancer, as an immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy.
Estonian: Bikalutamiid on suu kaudu manustatav antiandrogeen, mida kasutatakse paikselt kaugelearenenud eesnäärmevähiga patsientide vahetuks raviks kas ainsa ravina või radikaalse prostatektoomia või kiiritusravi adjuvantravina.
English: Helsingborg Sweden
Estonian: SE - 25110 Helsingborg Rootsi
English: Pharmachemie B.V. Swensweg 5, Postbus
Estonian: Pharmachemie B.V.
English: The valid package leaflet is the final version achieved during the Coordination group procedure with the following amendments:
Estonian: Koordineerimisrühma menetluse tulemusena saavutatud lõplik versioon on kehtiv pakendi infoleht koos järgmiste parandustega.
English: Based on these conclusions, the CHMP considered generic Bicalutamide 150mg film-coated tablets (Ingers Industrial Solutions s.r.o.)
Estonian: Nende järelduste põhjal pidas inimtervishoius kasutatavate ravimite komitee geneerilise ravimi Bicalutamide 150 mg õhukese polümeerikattega tabletid (Ingers Industrial Solutions s.r.o.)
English: Events (%) in placebo patients
Estonian: Juhud (%) platseebopatsientidel
English: 2740-264 Porto Salvo, Portugal
Estonian: Lagoas Park, Edifício 1, Piso 3, 2740-264 Porto Salvo Portugal
English: Table 1 Progression-free survival in locally advanced disease by therapy sub-group Analysis population Events (%) in Bicalutamide patients
Estonian: Tabel 1 Progressioonivaba elulemus lokaalse kaugelearenenud haiguse korral ravi alamgruppide järgi
English: Table 2 Overall survival in locally advanced disease by therapy sub-group Analysis population Deaths (%) in Bicalutamide patients
Estonian: Tabel 2 Üldine elulemus lokaalse kaugelearenenud haiguse korral ravi alamgruppide järgi
English: 2003 RN Haarlem The Netherlands
Estonian: Swensweg 5, Postbus 552, 2003 RN Haarlem Madalmaad
English: The Committee, considering the Casodex Referral (bicalutamide 150 mg) made under article 31 of Directive 2001/83/EC for medicinal products containing bicalutamide, reached the conclusion that bicalutamide 150mg is effective in the treatment of locally advanced prostate cancer; however the CHMP considered that the therapeutic indication should be restricted to: “Bicalutamide 150mg is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression”.
Estonian: Võttes arvesse seoses ravimiga Casodex (bikalutamiid 150 mg) direktiivi 2001/83/EÜ artikli 31 alusel bikalutamiidi sisaldavate ravimite kohta esitatud esildist, jõudis komitee otsusele, et bikalutamiid 150 mg on paikselt kaugelearenenud eesnäärmevähi raviks efektiivne.
English: The valid summary of product characteristics is the final version achieved during the Coordination group procedure with the following amendments:
Estonian: Koordineerimisrühma menetluse tulemusena saavutatud lõplik versioon on kehtiv ravimi omaduste kokkuvõte koos järgmiste parandustega.
English: WHAT BICALUTAMIDE IS AND WHAT IT IS USED FOR Bicalutamide belongs to the group of anti-androgens.
Estonian: Bikalutamiid kuulub antiandrogeenide rühma.
English: BicamidGRY 150 mg Filmtabletten
Estonian: Bicamid-GRY 150 mg Filmtabletten
English: Filmtabletten
Estonian: Analüüsi grupp
English: (Invented) Name
Estonian: Nimi
English: Bicalutamide 150 mg Filmcoated
Estonian: Bicalutamide 150 mg Film-coated Tablets
English: BicalutamideTEVA
Estonian: Manustamisviis
English: Bicaluplex 150 mg
Estonian: Bicaluplex 150 mg 150 mg Õhukese polümeerikilega kaetud tabletid
English: The studies in human involved a total of 222 patients in two main studies.
Estonian: Inimestel tehtud uuringutes osales kahes põhiuuringus 222 patsienti.
English: International non-proprietary name (INN): glucarpidase
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): glükarpidaas
English: The letter from the company notifying the EMEA of the withdrawal of the application is available here.
Estonian: Ettevõtte kiri, mis teavitas EMEAt taotluse tagasivõtmisest, on kättesaadav siit.
English: If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.
Estonian: Kui osalete kliinilises uuringus või ravimi eriloaga kasutamise programmis ja vajate rohkem teavet oma ravi kohta, võtke ühendust arstiga, kes teile selle määras.
English: The main measure of effectiveness was the reduction in blood levels of methotrexate.
Estonian: Peamine tõhususe näitaja oli metotreksaadi taseme vähenemine veres.
English: The application was at day 180 when the company withdrew.
Estonian: Taotluse menetlemine oli kestnud 180 päeva, kui ettevõtte taotluse tagasi võttis.
English: These toxic effects can be life-threatening.
Estonian: Need toksilisuse nähud võivad olla eluohtlikud.
English: Methotrexate is used to treat a number of diseases, including some types of cancer.
Estonian: Metotreksaati kasutatakse mitmete haiguste, sealhulgas ka teatud tüüpi vähkkasvajate raviks.
English: The Committee had concerns that this move was not yet fully organised, especially with regards to the way the production would be controlled (validation), and that the consequences of the move on the product's purity were not been fully understood.
Estonian: Komitee arvas, et selline üleviimine ei olnud veel täielikult organiseeritud, eriti tekitas küsimusi tootmisprotsessi kontrollimine (valideerimine), ning et tootmise üleviimise tagajärjed toote puhtusele ei ole veel täpselt teada.
English: What is Voraxaze?
Estonian: Mis on Voraxaze?
English: The production of the medicine had moved from the factory that made the medicine used in the studies, to another factory that was to make the commercial product.
Estonian: Ravimi tootmine oli viidud tehasest, mis valmistas uuringutes kasutatud ravimit, teise tehasesse, mis pidi hakkama valmistama turustatavat toodet.
English: Following the CHMP's opinion, it usually takes around two months for the European Commission to grant a licence.
Estonian: Pärast inimtervishoius kasutatavate ravimite komitee otsust kulub Euroopa Komisjonil müügiloa andmiseks ligikaudu kaks kuud.
English: It contains the active substance glucarpidase.
Estonian: See sisaldab toimeainet glükarpidaasi.
English: The company also plans to continue their compassionate use programme.
Estonian: Ettevõte plaanib jätkata ka ravimi eriloaga kasutamise programme.
English: Voraxaze was not compared to another treatment.
Estonian: Voraxazet ei võrreldud teiste ravimeetoditega.
English: This helps the body eliminate excess methotrexate, and therefore reduces the potential for toxic effects.
Estonian: See aitab eemaldada organismist liigset metotreksaati ning seetõttu vähendada toksilisuse nähtude ilmnemise võimalust.
English: London, 21 June 2007 Doc.
Estonian: London, 21. juuni 2007 Viitedokument: EMEA/381420/2007
English: The recombinant enzyme acts in the same way as the natural carboxypeptidase G2.
Estonian: Rekombinant-ensüüm toimib samal viisil nagu looduslik karboksüpeptidaas G2.
English: Once the company has supplied responses to the questions, the CHMP reviews them and may, before giving an opinion, ask any remaining questions at day 180.
Estonian: Kui ettevõte on küsimustele vastanud, vaatab inimtervishoius kasutatavate ravimite komitee vastused üle ja võib enne otsuse tegemist esitada 180. päeval veel küsimusi.
English: Because the number of patients with this condition is low, it is considered ‘rare', and glucarpidase was designated an ‘orphan medicine' (a medicine used in rare diseases) on 3 February 2003.
Estonian: Et selle seisundiga patsientide arv on väike ja seda peetakse harvaesinevaks seisundiks, anti 3. veebruaril 2003 glükarpidaasile harva kasutatava ravimi nimetus (ravim, mida kasutatakse harva esinevate haiguste korral).
English: After the CHMP had assessed the responses from the company to a list of questions, there were still some unresolved issues outstanding.
Estonian: Pärast seda, kui inimtervishoius kasutatavate ravimite komitee oli hinnanud ettevõttele esitatud küsimuste vastuseid, jäid siiski lahendamata mõned olulised probleemid.
English: It can break down methotrexate into substances that do not have any toxic effects.
Estonian: See suudab metotreksaadi lagundada ühenditeks, millel toksilised toimed puuduvad.
English: Some cancer patients receive high doses, and, because of this, can experience toxic effects, such as damage to the kidneys, bone marrow suppression (leading to anaemia, an increased risk of infection and bleeding) and mucositis (an inflammation of the mucosa, the lining of organs such as the mouth, with soreness, redness and ulceration).
Estonian: Mõned vähkkasvajaga patsiendid saavad suures annuses metotreksaati ning neil võivad seetõttu tekkida toksilisuse nähud, nagu näiteks neerukahjustus, luuüdi tegevuse pärssimine (põhjustabs aneemiat, mis tähendab nakkus- ja veritsusohu suurenemist) ja limaskestapõletikud (limaskesta, näiteks suu sisekesta valulikkus, punetus ja haavandid).
English: What documentation did the company present to support its application to the CHMP?
Estonian: Missugused dokumendid ettevõte inimtervishoius kasutatavate ravimite komiteele oma taotluse toetuseks esitas?
English: QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for VORAXAZE
Estonian: TEAVE MÜÜGILOA TAGASIVÕTMISE KOHTA VORAXAZE
English: The glucarpidase in Voraxaze is made by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA) that makes it able to produce it.
Estonian: Voraxazes olev glükarpidaas toodetakse rekombinant-DNA-tehnikana tuntud meetodil: ensüümi toodavad bakterid, millesse on lisatud selle teket võimaldav geen (DNA).
English: The company informed the CHMP that there are no consequences for patients currently included in the clinical trials of Voraxaze.
Estonian: Ettevõte teavitas inimtervishoius kasutatavate ravimite komiteed, et tagajärjed Voraxaze kliinilistesse uuringutesse hetkel kaasatud patsientidele puuduvad.
English: All patients received the medicine as part of a compassionate use programme: the doctor requested Voraxaze from the manufacturer as soon as they encountered a patient with methotrexate toxicities who could possibly benefit from the medicine.
Estonian: Kõik patsiendid said ravimit eriloaga kasutamise programmi raames: arst taotles tootjalt Voraxazet kohe, kui hakkas ravima metotreksaadi toksilisuse nähtudega patsienti, kes võis sellest ravimist kasu saada.
English: Folinic acid can also be broken down in the body by Voraxaze, and further studies should be carried out to look at the consequences of this when managing patients with methotrexate toxicities.
Estonian: Ka foolhape võib kehas laguneda Voraxaze toimel, mistõttu on vaja läbi viia täiendavaid katseid, et uurida selle toime tagajärgi metotreksaadi toksilisuse nähtudega patsientidele.
English: Voraxaze was to be given to adults or children as a single injection if the level of methotrexate in the patient's blood was above a given ‘threshold' at certain times after administration of methotrexate.
Estonian: Voraxazet kavatseti täiskasvanutele või lastele manustada ühekordse süstena, kui metotreksaadi tase patsiendi veres ületas teatud ajal pärast metotreksaadi manustamist etteantud läve.
English: The Committee also had some concern regarding the use of Voraxaze with folinic acid.
Estonian: Lisaks valmistas komisjonile muret Voraxaze kasutamine koos foolhappega.
English: What are the consequences of the withdrawal for patients undergoing clinical trials / compassionate use programmes with Voraxaze?
Estonian: Millised on taotluse tagasivõtmise tagajärjed praegu Voraxaze kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
English: On 21 May 2007, Protherics PLC officially notified the Committee for Medicinal Products for Human Use (CHMP) that they wish to withdraw their application for a marketing authorisation for Voraxaze, for the adjunctive treatment of patients experiencing or at risk of methotrexate toxicity.
Estonian: 21. mail 2007 teatas Protherics PLC ametlikult inimtervishoius kasutatavate ravimite komiteele oma otsusest võtta tagasi ravimi Voraxaze müügiloa taotlus.
English: Voraxaze is a powder to be made up into a solution for injection.
Estonian: Voraxaze on pulber, millest valmistatakse süstelahus.
English: Based on the review of the data and the company's response to the CHMP list of questions at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Voraxaze could not have been approved for the adjunctive treatment of patients experiencing or at risk of methotrexate toxicity.
Estonian: Tuginedes esitatud andmete analüüsile ja vastustele, mis ettevõte inimtervishoius kasutatavate ravimite komitee poolt koostatud küsimustele andis, väljendas inimtervishoius kasutatavate ravimite komitee taotluse tagasivõtmise ajal murelikkust ja oli esialgu seisukohal, et Voraxaze kasutamist metotreksaadi toksilisuse nähtudega või nende tekke riskiga patsientide täiendavaks raviks ei ole võimalik heaks kiita.
English: Voraxaze would have been used either as a treatment in patients who had developed such toxic effects, or as prevention in patients who were at risk of developing them, such as patients who have high levels of methotrexate in their blood, or those who have poorly functioning kidneys (when methotrexate may be eliminated more slowly).
Estonian: Voraxazet oleks kasutatud kas ravimina patsientidel, kellel sellised toksilisuse nähud on juba tekkinud, või ennetava ravimina patsientidel, kes on nende nähtude tekkest ohustatud, nagu näiteks patsiendid, kelle veres sisaldub palju metotreksaati, või patsiendid, kelle neerud talitlevad puudulikult (sel juhul eritatakse metotreksaati kehast aeglasemalt).
English: Another medicine, folinic acid, is often given after the methotrexate to help control the toxicities (‘rescue' treatment) but these may still develop despite the rescue treatment.
Estonian: Metotreksaadi järel antakse sageli veel teist ravimit, foolhapet, et aidata vähendada toksilisi toimeid (niinimetatud kaitseravim), kuid toksilisuse nähud võivad tekkida sellele vaatamata.
English: How is Voraxaze expected to work?
Estonian: Milline on Voraxaze eeldatav toime?